Keppra
Photosensitive Epilepsy
The Epilepsy Study ConsortiumPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Photosensitive Epilepsy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Valproic Acid Vanderbilt University Medical Center | Phase 4 | BB |
Benzeneethanamine, N-ethyl-?-methyl-4-(trifluoromethyl)-, hydrochloride, (±)- Elizabeth Anne Thiele | Phase 3 | BB |
Brv Rosenfeld, William E., M.D. | Phase 2/3 | B |
Carbamazepine The Epilepsy Study Consortium | Phase 2 | B |
SELURAMPANEL Novartis Pharmaceuticals | Phase 2 | B |
View all 10 →
Same molecule, other indications
Keppra is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →